Bronchoscopic Microwave Ablation of Lung Tissue

Lung Cancer Clinical Trial

— AB1MALT  

Official title:

Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05786625
• Other study ID #: 8-AB1-950
• Status: Recruiting
• Start date: May 4, 2023
• Est. completion date: March 2025

Study information

• Verified date: July 2023
• Source: Creo Medical Limited
• Contact: Patrick Burn
• Phone: +44 1291 606 005
• Email: Patrick.Burn[@]creomedical.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety and feasibility of the Creo Medical MicroBlate™ Flex AB1 instrument used with the AB1 electrosurgical system in patients undergoing bronchoscopic microwave ablation of peripheral lung nodules.

Description:

This is a post-market, prospective, single-arm, multicentre, non-randomized, observational study which will enrol up to 32 subjects in total (plus replacements) at up to 6 clinical investigation sites in Europe and potentially 1 site in the US. Prospective patients must have a suitable soft tissue lung lesion and be candidates for an elective endobronchial navigation and microwave ablation procedure performed bronchoscopically. After being informed about the study and potential risks, all patients giving their written informed consent will undergo a screening visit to determine eligibility for study entry. Patients who meet the eligibility requirements will undergo a pre-procedural assessment, a bronchoscopy procedure that includes ablation treatment with MicroBlate™ Flex AB1, a post-procedural assessment and 6 follow-up visits at, 7 days (by phone call or in person), 31-45 days, 3 months, 6 months, 9 months and 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: March 2025
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

The participant may enter the study if ALL of the following apply:

The patient:

1. Has signed the informed consent form

2. Are = 18 years old

3. Has lung lesion(s)/nodule(s) which are histologically confirmed or highly suspicious for cancer (as determined by a multi-disciplinary board).

4. Has a medically inoperable soft tissue lung lesion(s) = 20 mm (suspected or confirmed malignancy), or patient has elected not to have surgery / alternative therapy.

5. Patient is a candidate for bronchoscopy under general anaesthesia.

6. Subject is willing and able to comply with the study protocol requirements.

7. Are assigned an ASA (American Society of Anaesthesiologists) score of = 3 or the patient is deemed unfit for general anaesthesia. Exclusion Criteria:

The participant may not be enrolled in the study if ANY of the following apply:

1. Target nodule(s) are within the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, oesophagus, spinal cord and phrenic & laryngeal nerves), or are <10 mm from the pleura.

2. Are assigned status 4 via ECOG (Eastern Cooperative Oncology Group) classification.

3. Are pregnant or breast feeding, as determined by standard site practices.

4. Have participated in an investigational drug or device research study within 30 days of enrolment that would interfere with this study.

5. Are scheduled for concurrent interventional procedure for the target soft tissue lesion.

6. Have a physical or psychological condition or other factor(s) that would impair study participation, or jeopardise the safety or welfare of the subject.

7. Have an expected survival less than 6 months.

8. Have patients with bleeding diathesis, uncorrectable coagulopathy or platelet count = 100 x 10? /L.

9. Have an implantable devices, including pacemakers or other electronic implants.

10. Have known pulmonary hypertension (PASP [pulmonary artery systolic pressure] >50mmHg).

11. Who are currently prescribed anticoagulants, clopidogrel or other platelet aggregation inhibitors which cannot be stopped or temporarily withheld.

12. Any patient with clinically significant interstitial lung disease in the zone of planned ablation.

13. Patient has nodal disease confirmed through invasive or image-based staging. Note: if nodal disease is suspected or detected during the staging procedure conducted prior to use of the investigational device during the study procedure, the subject will be excluded.

14. Subject had a prior pneumonectomy.

Related Conditions & MeSH terms

• Lung Cancer

Intervention

Device:
• Ablation
Bronchoscopy and microwave ablation of lung nodule

Locations

Country	Name	City	State
United Kingdom	Royal Brompton and Harefield NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Creo Medical Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Safety Endpoint	Identification of serious device-related adverse events related to the use of the AB1 system up to 30 days after the ablation procedure (number and nature of serious adverse events, both device- and procedure- related, will be identified) including, but not limited to: Moderate bleeding (intervention required such as use of balloon tamponade or Surgicel) or severe bleeding (prolonged monitoring necessary or fatal bleeding); Pneumothorax; Failure of extubation; ICU admission for respiratory failure within 30 days; Death within 30 days.; The endpoint will be met if no serious device-related (causal relationship) adverse events occur that have not been previously identified in the Protocol, the literature or Risk Assessments for the AB1 system.	Up to 30 days after the ablation procedure.
Primary	Primary Performance (Efficacy) Endpoint	Initial technical success, defined as successful bronchoscopic access by the AB1 instrument of the target tissue, delivery of the scheduled microwave energy to the target tissue and confirmed ablation as evidenced by assessment of CT.; The criterion for meeting the Performance (efficacy) endpoint excludes study system malfunctions.	Up to day 30 patient visit.
Secondary	Secondary Safety Endpoint	Identification of all device-related, procedure related and other adverse events related to bronchoscopic microwave ablation interventions using the AB1 system.	Up to 12 months post ablation.
Secondary	Secondary Effectiveness Outcomes - Rate of tumor recurrence	Rate of recurrence at all time points as determined by the multidisciplinary team (MDT) or tumour board.	Up to 12 months
Secondary	Secondary Effectiveness Outcomes - European Organization for Research and Treatment of Cancer Quality of life questionnaire - Cancer (EORTC QLQ-C)	Patients will rate their responses from 1 to 4 on a Likert Scale (1 being "not at all" and 4 being "very much").	Up to 12 months
Secondary	Secondary Effectiveness Outcomes - EQ-5D-5L health-related quality of life questionnaire	Patients complete the 5 level descriptive system relating to 5 dimensions of health and the EQ visual analogue scale from 0 to 100 (where 0 means the worst health you can imagine and 100 means the best health you can imagine).	Up to 12 months
Secondary	Secondary Effectiveness Outcomes - Patient-reported pain rating on a visual analogue scale	Patients will rate their pain on a visual analogue scale from 0 to 10 (where 0 is no pain and 10 is the most severe pain).	Up to 45 days post-ablation
Secondary	Secondary Effectiveness Outcomes - Assessment/visualization/quantification of the dimensions of the ablated tissue	Dimensions of the ablated tissue to confirm, correct or add to the IFU-reported relationship between AB1 ablation time and dimensions and volume of the ablated tissue, per pre-specified target.	Up to 12 months
Secondary	Secondary Effectiveness Outcomes - Procedural Time	Procedural time to be captured in the electronic case report form (eCRF).	Up to 1 day post ablation procedure.
Secondary	Secondary Effectiveness Outcomes - Assessment of ease of system use (clinician questionnaires)	Questionnaires to be completed by clinicians, rating their responses on a Likert scale of 1 to 7, with 1 being "extremely easy" and 7 being "extremely difficult".	Up to 1 day post ablation procedure.